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Abstract For patients with type 1 diabetes, innovations in
insulin formulations and delivery have improved the ability to
achieve excellent blood glucose control. However, it is
uncommon to achieve euglycemia, particularly while avoiding
complications arising from hypoglycemia. Pancreas transplan-
tation remains the only broadly applied treatment strategy that
can result in normalization of blood glucose, but this must be
weighed against the risks of a surgical procedure and
subsequent immunosuppression. To improve this risk/benefit
ratio, pancreas transplantation is typically performed in patients
with kidney failure who are to undergo kidney transplantation
and immunosuppression (simultaneous pancreas-kidney trans-
plant) or who have undergone kidney transplant and are
obligated to the use of immunosuppressive medications
(pancreas after kidney transplant). The purpose of this review
is to clarify the benefit of an added pancreas transplant in these
clinical settings and formulate an approach to the patient with
type 1 diabetes as they approach kidney failure.
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Introduction
Significant improvements in the management of type 1
diabetes mellitus (T1DM) have resulted in a decrease in the
projected incidence of kidney failure over time. Once
considered to impact 15% of patients who survive with
diabetes for 30 years [1], a recent epidemiologic study
suggests that the incidence of kidney failure may now be less
than 8% [2]. The benefits of intensive blood glucose control
on the progression of kidney disease have been well
documented; the DCCT (Diabetes Control and Complica-
tions Trial) and EDIC (Epidemiology of Diabetes Interven-
tions and Complications) cohort of 1349 subjects reported a
total of only 11 cases of end-stage renal disease over a mean
duration of diabetes of nearly 20 years, with a mean
hemoglobin A1c of 7.2% and 8.0% in the 6.5 and 8 years
of consecutive follow-up that these trials provided [3, 4].
Unfortunately, many patients cannot achieve the degree of
blood glucose control that is reported in the setting of a
clinical trial, or suffer untoward effects of hypoglycemia with
aggressive control that can threaten quality of life and be life-
threatening. There remains a need for additional therapeutic
options for these patients. Pancreas transplantation can offer
the benefits of normalization of blood glucose control but at
the risk of a surgical procedure and the requirement of
antirejection medications to sustain pancreas function. Fortu-
nately, advances in surgical outcomes and immunosuppres-
sion over the past decade have made pancreas transplantation
a more attractive option for patients with T1DM and kidney
failure, and have led to a reconsideration of the most
appropriate timing of the procedure in relation to an
individual’s kidney function (either as a simultaneous
pancreas-kidney transplant [SPK], a pancreas after kidney
transplant [PAK], or pancreas transplant alone [PTA]).
The Critical Role of Kidney Transplantation in Patients
with T1DM
For patients with T1DM who suffer from progressive
kidney disease, it is imperative that proper education
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proactively due to the significant negative impact dialysis
imparts upon patient survival, and the dramatic benefits that
can be achieved with kidney transplantation. For patients
with diabetes who are placed on a waiting list for kidney
transplantation but remain on dialysis, the mean survival is
8 years, whereas for those who receive a kidney the mean
survival is 22 years [5]. Similarly, for those who are eligible
for a combined kidney pancreas transplant (likely a slightly
healthier population due to acceptance criteria), patients
who remain on dialysis have an estimated mortality of 40%
at 4 years, whereas those who receive SPK transplants have
a mortality of 10% [6]. The timing of kidney transplanta-
tion is also a critical determinant to outcomes. If performed
before the need for dialysis (preemptive transplant), kidney
transplants from a living donor result in a 43% reduction in
risk of death compared with transplant after the onset of
dialysis, whereas kidney transplants from a deceased donor
are associated with a 12% reduction in risk of death [7].
Given these dramatic differences in outcomes, patients with
T1DM and estimated glomerular filtration rate (GFR) of
30 mL/min should be referred to a transplant center for
pretransplant evaluation and counseling regarding potential
transplant options.
The Impact of Pancreas Transplantation in Kidney
Transplant Candidates and Recipients
For an individual patient with T1DM and progressive renal
disease, transplant options include kidney transplant alone
(from a deceased or living donor [DDKA, LDKA]) or SPK.
The benefits of adding a pancreas to a kidney transplant
should be considered in terms of “hard” end points (ie, the
impact on patient and kidney graft survival) and “softer”
end points (ie, the benefits of euglycemia on quality of life
and other secondary complications of diabetes such as the
impact on neuropathy, retinopathy, and cardiovascular
disease).
Pancreas Transplantation and Patient Survival, Kidney
Graft Survival
Regarding patient survival, it is clear from numerous
retrospective analyses and data registries that an SPK
procedure is associated with a higher postoperative mortal-
ity of about 2% in the first 90 days compared with kidney
alone (KA) [8, 9￿]. This difference is mitigated by about 12
to 24 months when compared with DDKA, and patient
survival is markedly improved thereafter for SPK. This is
likely due not only to the euglycemia that is provided by
the pancreas transplant, but also is related to differences in
deceased donor characteristics of an SPK donor versus a
KA donor [10￿, 11￿]. Only about 15% to 20% of deceased
organ donors are suitable for both pancreas and kidney
donation [12, 13], and these donors are younger, with lower
body mass index (BMI) and less comorbidities prior to
brain death than donors who are not pancreas donors [14].
When comparing kidney graft survival in SPK recipients
and DDKA recipients, again the SPK provides better
outcomes than DDKA, beginning as early as 12 months
after the procedure.
The benefits of SPK over LDKA are more subtle than
those noted compared with DDKA, primarily due to a
significantly lower risk of death in the postoperative period
with the LDKA procedure [15￿]. With LDKA, recipients
are known to be clinically stable at the time of surgery
rather than “on call” for potential transplant, the donor is
extensively evaluated, the surgery is done on a scheduled
basis with a minimum of time from kidney removal to
transplantation (“cold ischemia time”), and is less complex
than an SPK procedure, all of which lead to fewer
postoperative complications and immediate graft function.
For these reasons, 1-year mortality for SPK versus LDKA
is 5%, versus 2% to 3%, from various reports [9￿, 15￿].
Three important recent publications have addressed the
value of SPK versus LDKA and DDKA in retrospective
analyses using three separate transplant registries. Using the
Organ Procurement and Transplantation Network/United
Network of Organ Sharing database (comprised of kidney
transplant and pancreas transplant recipients in the United
States), Young et al. [16￿￿] compared kidney graft and
patient survival differences with SPK, LDKA, and DDKA
over the period 2000 to 2007. One-year survival was
highest in the LDKA cohort and lowest in the DDKA
cohort (95%, 97%, and 93%, respectively), as was kidney
graft survival (93%, 95%, and 89%, respectively). These
differences persisted for 5 to 6 years, following which time
the outcomes of SPK and LDKA began to shift in favor of
SPK. At 6 years, patient survival was higher in the SPK
cohort with similar kidney graft survival to LDKA (patient
survival 85%, 80%, and 69%, and graft survival 72%, 72%,
58%, respectively). Although Young et al. [16￿￿] concluded
that LDKA should be pursued whenever possible due to
unpredictable organ availability and at least equivalent if
not better outcomes with LDKA than SPK over a 5- to 6-
year period, these data suggested that patients with T1DM
may derive greater benefits in the long term from SPK.
Morath et al. [17￿￿] clarified this point using data from the
Collaborative Transplant Study (comprised of transplant
centers in the United States and internationally). In patients
with kidney function at 10 years post-transplant, those who
had received SPK had a significantly better survival rate
over the following 8 years than patients who had received
an LDKA or DDKA. This improved survival was noted
particularly in those patients with functioning pancreas
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death in particular, leading the authors to conclude that long-
term glycemic control in SPK recipients conferred a survival
benefit over LDKA, due to less progression of cardiovascular
disease. A follow-up analysis from the same group suggested
that the benefit of a pancreas transplant outweighs the early
risk of the surgical procedure at about 9 to 10 years after
transplant irrespective of pancreas function [18].
This “delayed gratification” for a survival benefit with
SPK poses questions regarding if this is an appropriate
alternative to LDKA when a living kidney donor is
available. This is particularly problematic when one
considers that the median pancreas life span is slightly
greater than 10 years, and that 15% of SPK recipients lose
pancreas graft function within the first year [15￿]. To better
understand the hazards of early pancreas graft loss and the
benefits of early pancreas graft function on long-term
survival, Weiss et al. [19￿￿] compared patients considered
healthy enough to be SPK candidates but received LDKA
and DDKA to patients who received SPK. This analysis
examined survivors at 12 months who had kidney function,
and segregated the SPK cohort into those who had pancreas
function at 12 months (SPK,P+) versus those with loss of
function (SPK,P-). The SPK(P+) cohort had significantly
better estimated survival throughout the following 7 years
(88.6%) than the remaining three groups, including the
LDKA group (80.0%), which had a nonstatistically better
survival advantage over those SPK recipients who had lost
function in the first year (SPK,P-; 73.9%). This point was
reiterated in a large single-center analysis that demonstrated
that in the 12% of SPK recipients who had early loss of
pancreas function (within 90 days), patient and kidney graft
survival were significantly worse than SPK recipients with
early function of the pancreas [20].
Based on the findings of these three analyses, the
following conclusions can be drawn: 1) DDKA is inferior
to LDKA or SPK for both patient and kidney graft survival;
2) the increased mortality of about 2% and pancreas graft
loss of 10% to 15% for SPK in the first year leads to
slightly better LDKA patient survival for a least 6 years; 3)
SPK ultimately leads to improved patient survival, and is
dependent on pancreas function; 4) with present-day
outcomes, it can be expected that about 85% of SPK
recipients will derive greater survival benefit from SPK
versus LDKA, which can be evident as early as 12 months
post-transplant (Table 1).
Pancreas Transplantation and Secondary Complications
of Diabetes
Unfortunately, few recent trials have been performed that
examine the effect of normalization of blood glucose
with pancreas transplant on complications such as
retinopathy, neuropathy, and nephropathy. Further, these
trials often are small and without adequate control
groups, or use surrogate markers of improvement that
may not reflect improvements that may be noted clinically.
Highlights of these trials will be briefly reviewed as they are
often used as criteria to consider PTA in patients with early
renal disease.
The prevention of diabetic nephropathy (DN) is often
raised as an indication for PTA, prior to severe kidney
failure. The most widely accepted study addressing the
potential for stabilization or reversal of DN is a case series
of eight PTA recipients who maintained pancreas graft
function for 10 years, who underwent assessment and
kidney biopsy at 0, 5, and 10 years post-PTA [21].
Microalbuminuria resolved, and the early histologic find-
Table 1 Summary of advantages and disadvantages of transplant options for diabetic kidney disease
Advantages Disadvantages
DDKA Provides better survival than dialysis options Inferior to other transplant options with respect to
kidney graft survival and patient survival
LDKA Minimizes waiting time, time spent on dialysis No normalization of blood glucose
Very low early morbidity and mortality Inferior patient survival over time when compared
with SPK recipients with functioning grafts Better survival initially than with SPK
SPK Glycemic control, with recent median pancreas
graft survival of >10 years
Higher morbidity and mortality due to larger operation
High-quality, deceased donor kidney transplant. If pancreas fails within the first year, outcomes are
worse than LDKA
PAK Glycemic control Two separate surgical procedures, increased mortality
early postoperatively following pancreas transplant
If living donor kidney transplant, comparable/better
patient and kidney graft survival than LDKA
Historically inferior pancreas graft survival (35% at
10 years) than SPK
DDKA deceased donor kidney alone, LDKA living donor kidney alone, PAK pancreas after kidney transplant, SPK simultaneous pancreas-kidney
transplant
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until the 10-year biopsy. Further, estimated GFR fell 30%
early in the study, presumably due to the vasoconstrictive
and nephrotoxic immunosuppressive agent cyclosporine.
Current recommendations for immunosuppression for all
types of pancreas transplants (SPK, PAK, and PTA) all
include a calcineurin inhibitor such as tacrolimus or
cyclosporine. Given this trade-off in GFR for stabilization
of DN, PTA should not be recommended solely for
prevention of DN. Diabetic retinopathy may improve,
stabilize, or deteriorate following the pancreas transplanta-
tion [22–24]. One recent study compared 33 patients
following PTA with a control group of 35 patients with
similar baseline degree of retinopathy. Over a mean
follow-up of 2.5 years, 91% of patients improved or
stabilized in the PTA cohort versus 43% in the control
group (P<0.01) [22]. Finally, early studies using surrogate
markers (electrophysiologic measures) of diabetic neurop-
athy have suggested a beneficial impact on neuropathy,
with improvements in gastric emptying and sensory and
motor neuropathy [25, 26]. Aside from improvements in
patient and kidney graft survival, perhaps the most
valuable benefit achieved with pancreas transplantation
is the avoidance of hypoglycemia unawareness and
improvement in diabetes-related quality of life [27, 28].
Hyperinsulinemic clamp studies in PTA recipients dem-
onstrate improvement in glucagon and epinephrine
responses and symptom recognition that persisted up to
19 years after PTA [29]. In total, these studies suggest that
pancreas transplant may result in improvements in early
complications of diabetes and result in improved diabetes-
related quality of life, but may not be as successful in
more advanced disease [30], and further controlled studies
are needed.
SPK Transplantation or PAK Transplantation?
For the patient who selects the option of LDKA rather than
wait for an SPK (either due to the increased mortality risk
noted above or an unacceptably long waiting time for an
appropriate deceased donor), another question emerges:
what are the risks and benefits of an added pancreas
transplant following kidney transplant (PAK)? Unlike the
comparison of SPK versus remaining on dialysis, in
which the mortality while accumulating time on dialysis
is significant and leads to a clear advantage for SPK, it is
difficult to overcome the risks of pancreas transplant
surgery and demonstrate a benefit when comparing
PAK versus LDKA due to the low mortality rates of
LDKA recipients. This is best demonstrated by comparing
two studies that examined PAK outcomes from registry
data.
From PAK performed in l995 to 2000, Venstrom et al.
[31] showed a nearly threefold increased risk of death in the
90 days following PAK compared with “conventional
therapy” following kidney transplant alone, and although
this risk dissipated over time, PAK was associated with a
42% increased risk of death at 4 years following transplant.
Gruessner et al. [6] performed a similar analysis of PAK
recipients from 1995 to 2003. They also showed a greater
than fourfold increased risk of death in the first 90 days, but
unlike Venstrom et al. [31], this risk was entirely mitigated
due to a reduction in risk after 1 year (hazard ratio for
death, 0.18; PAK vs conventional therapy, P<0.001), and
there was no increased risk of death overall. Differences in
study design between these reports that account for these
different conclusions include exclusion of patients with a
creatinine greater than 2.0 in the report by Venstrom et al.
[31] (thus creating a healthier waiting list for comparison)
and the longer study period (9 vs 5 years) by Gruessner et
al. [6] (thus permitting the benefits of glycemic control to
emerge). Overall, these findings suggest that the mortality
risk of an added pancreas surgery after kidney transplant is
not overcome at 4 years but that PAK perhaps is
advantageous with longer follow-up.
Several recent reports have shed a more favorable light
on PAK transplant following LDKA (pancreas after living
kidney transplant [PALK]). In a large registry analysis
comparing patients receiving LDKA with those who
received a PALK during the period 1997 to 2007, 8-year
estimated patient (85% vs 75%) and kidney graft survival
(75% vs 62%) were superior in the PALK group, with
advantages that persisted after correction for other comor-
bidities and when examining patients with kidney function
at 1 year following LDKA [32￿]. A single-center report
compared 175 patients who underwent PALK with 75
patients who received LDKA and were eligible for PAK but
did not receive a pancreas transplant due to financial or
personal reasons [33]. Patient survival and kidney graft
survival were equivalent at 1, 5, and 10 years, better
hemoglobin A1c was achieved in PALK versus LDKA, and
better GFR over time was noted in those PALK who had a
pancreas transplant 2 to 12 months following kidney
transplant. These reports suggest that the mortality risk of
pancreas transplant may be minimized in a more modern
era and in experienced pancreas transplant centers, favoring
PALK over LDKA.
These improvements in PALK outcomes occurred
despite the fact that pancreas graft function is considerably
shorter in the setting of PAK than SPK. From 2004 to 2008,
the1- and 3-year pancreas function rates for SPK were 85%
and 78%, whereas for PAK these rates were 79% and 65%,
respectively [9￿]. These differences appear to be due to a
higher rate of acute and chronic rejection in the setting of
PAK (at 3 years, graft loss due to immunologic causes was
388 Curr Diab Rep (2010) 10:385–39114% in PAK vs 5% in SPK), presumably because of a
separate antigenic stimulus in PAK and difficulty in
monitoring for isolated pancreas rejection. Single centers
have recently reported novel strategies of immunosuppres-
sion, primarily relying upon depleting T-cell induction
therapy, that have been associated with improvements in
pancreas graft function in the setting of PAK [34￿]. These
improvements have led to the suggestion that PALK may
be a preferred strategy over SPK. This recommendation
must be balanced with the recognition that PALK recipients
are a selected group of patients who have had favorable
initial kidney transplant outcomes and are considered
candidates for an additional immunosuppression and a
second operation (Table 1).
Opportunities for Growth of Pancreas Transplantation
Ultimately, the decision for a patient to receive an SPK or
receive a living donor kidney and consider a pancreas
transplant at a later date is dependent upon the waiting time
necessary to receive an SPK transplant. In the United States
there are significant regional variations in waiting time for an
SPK transplant. Some regions have a policy that all patients
awaiting SPK are combined with the kidney transplant
waiting list, whereas others have a separate SPK list. In the
former, waiting times for SPK are as long as for kidney
transplant alone, generally 4 to 5 years, whereas in the latter,
waitingtimeissignificantlyless,oftenlessthan1year.Efforts
to standardize the SPK waiting list policy nationally are
underway in patients with T1DM. Because patients who
receive an SPK enjoy the greatest survival benefit of all
transplanted patients compared with dialysis yet comprise
only 4% of the kidney transplant waiting list [35], a proposal
to ensure that a separate SPK waiting list with priority
over kidney transplantation alone has gained significant
support.
Although efforts to prioritize SPK organ allocation will
lead to improvements in the utility of organs transplanted (by
providing a greater lifetime benefit of kidney transplants
overall), this will not necessarily lead to a greater number of
SPK transplants performed overall. The pancreas is success-
fully transplanted from only 15% to 20% of potential
deceased organ donors, primarily due to perceived organ
quality by transplant centers. To understand reasons for
refusal of pancreata from deceased donors who appear
otherwise optimal for solid organ donation, we performed an
analysisofdonorcharacteristicsofsuccessfulpancreasdonors
and compared these donors with a groups of deceased donors
19 to 40 years of age whose liver and kidneys were
successfully transplanted [36]. This study revealed that
subjective assessments of organ quality formed the basis
for most unused donor pancreata, and the potential for
growth in pancreas transplant required better standardization
Patient with T1DM
and GFR < 30 mL/min
Living kidney donor available? 
Simultaneous
pancreas-kidney transplant
Patient on dialysis?
List for simultaneous 
pancreas-kidney transplant
Suitable candidate for simultaneous
pancreas-kidney transplantation?
Evaluate for kidney transplant alone
(living donor or deceased donor)
Pre-emptive simultaneous
pancreas-kidney transplant
Progression to or
nearing dialysisa
No
No
Yes
Ye s
No
Living donor kidney 
transplant alonea
Consider pancreas
after kidney transplant
Fig. 1 Therapeutic approach to
the patient with type 1 diabetes
mellitus (T1DM) and progressive
kidney failure (glomerular filtra-
tion rate [GFR] <30 mL/min)
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index” that uses 10 donor characteristics (including age,
BMI, cause of death, and donor renal function) was
demonstrated to predict pancreas graft function [37]. Ideally,
such objective assessments may lead to a greater utilization
rate of pancreata from deceased donors.
Evidence-based Recommendations
Given these recent advances, recommendations for patients
with T1DM approaching kidney failure should be tailored to
the individual’s circumstance, and should include an assess-
mentofthefollowing:1)Canalivingdonorcanbeidentified?
2) Is the patient (and transplant program) willing to accept a
higher risk of death and possibility of pancreas graft loss
(~ 2% and~15% in the first year, respectively) when
considering SPK? 3) How debilitating are the patient’s
diabetes-related quality-of-life issues and achieved level of
glycemic control? and 4) What is the expected waiting time
foranSPKinthepatient’sgeographicregion?Ingeneral,SPK
appears to offer advantages over KA (either DDKA or
LDKA) if the waiting time for a deceased donor is not
excessive, and dialysis time can be minimized (perhaps to
<6 months). For those patients who are unable to wait for
SPK, living donor kidney transplant followed by a later
pancreas transplant (PALK) appears to be associated with
better kidney graft function, with a risk of mortality that is
similar to LDKA (Fig. 1).
Conclusions
Pancreas transplantation can improve patient survival,
kidney graft function, and quality of life in patients with
T1DM and kidney disease. Recent improvements in
surgical outcomes and immunosuppression have translated
to improvements in graft function in both the SPK and PAK
setting, and national organ allocation policy is now
recognizing the need for emphasis of pancreas transplanta-
tion. With newer objective tools to assess the adequacy of
deceased donors for pancreas transplantation, it is hoped
that pancreas transplantation can expand and benefit a
substantially greater number of patients in the future.
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